Immunotherapy of type 1 diabetes: where are we and where should we be going?
Immunotherapy of type 1 diabetes: where are we and where should we be going?
复制标题
DOI：
10.1016/j.immuni.2010.04.002
复制
发表时间：
2010-04-23
期刊：
影响因子：
32.4
通讯作者：
Miller SD
中科院分区：
文献类型：
--
作者：
Luo X;Herold KC;Miller SD
1型糖尿病（T1D）是一种慢性自身免疫性疾病，其特征是产生胰岛素的胰腺β细胞被破坏。许多广泛的免疫抑制和抗原特异性免疫调节疗法已经并且目前正在评估其在预防和治疗T1D中的效用。展望未来，本文讨论了抗原特异性耐受策略的潜在治疗用途，包括由糖尿病源性抗原脉冲的耐受性抗原提呈细胞诱导的耐受性，以及在NOD小鼠中已证明有效的诱导或扩增调节性T细胞的转移。根据T1D疾病过程中治疗干预的时间，抗原特异性免疫调节策略可作为单一治疗，或与短期耐受性促进免疫调节药物和/或促进胰岛素生成β细胞从内源性祖细胞分化的药物联合使用。
Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of insulin-producing pancreatic β cells. Many broad-based immunosuppressive and antigen-specific immunoregulatory therapies have been and are currently being evaluated for their utility in the prevention and treatment of T1D. Looking forward, this review discusses the potential therapeutic use of antigen-specific tolerance strategies, including tolerance induced by tolerogenic antigen presenting cells pulsed with diabetogenic antigens and transfer of induced or expanded regulatory T cells which have demonstrated efficacy in NOD mice. Depending on the time of therapeutic intervention in the T1D disease process, antigen-specific immunoregulatory strategies may be employed as monotherapies, or in combination with short-term tolerance-promoting immunoregulatory drugs and/or drugs promoting differentiation of insulin-producing β cell from endogenous progenitors.
登录
查看更多内容
影响因子：
15.3
作者：
Bonifaz, L;Bonnyay, D;Mahnke, K;Rivera, M;Nussenzweig, MC;Steinman, RM
通讯作者：
Steinman, RM
影响因子：
3
作者：
Agardh, CD;Cilio, CM;Lernmark, Å
通讯作者：
Lernmark, Å
影响因子：
4.4
作者：
Chen, W;Bergerot, I;Delovitch, TL
通讯作者：
Delovitch, TL
DOI：
10.1073/pnas.94.9.4610
发表时间：
1997-04-29
影响因子：
11.1
作者：
Bergerot, I;Ploix, C;Thivolet, C
通讯作者：
Thivolet, C
影响因子：
158.5
作者：
BOUGNERES, PF;CAREL, JC;BACH, JF
通讯作者：
BACH, JF